• Explore /
  • Poster
  • / Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC).

Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC).

Abstract Poster

Authors

null

Michelino DeLaurentiis

National Cancer Institute “Fondazione Pascale,” Department of Breast and Thoracic Oncology, Naples, Italy

Michelino DeLaurentiis , Simona Borstnar , Mario Campone , Ellen Warner , Salvador Bofill , William Jacot , Susan Faye Dent , Miguel Martin , Alistair E. Ring , Paul H. Cottu , Janice M. Lu , Eva Ciruelos , Hamdy A. Azim , Sanjoy Chatterjee , Katie Zhou , Jiwen Wu , Nii Ankrah , Claudio Zamagni

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT02941926

Citation

J Clin Oncol 37, 2019 (suppl; abstr 1041)

DOI

10.1200/JCO.2019.37.15_suppl.1041

Abstract #

1041

Poster Bd #

122

Abstract Disclosures

Similar Posters

First Author: Tomás Pascual

First Author: Michelino DeLaurentiis

First Author: Yen-Shen Lu

First Author: Rachel M. Layman